Insider Selling: Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Sells 3,084 Shares of Stock

Tarsus Pharmaceuticals, Inc. (NASDAQ:TARS) General Counsel Bryan Wahl sold 3,084 shares of the firm’s stock in a transaction that occurred on Thursday, March 20th. The shares were sold at an average price of $50.11, for a total value of $154,539.24. Following the completion of the transaction, the general counsel now directly owns 51,712 shares in the company, valued at $2,591,288.32. The trade was a 5.63 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink.

Bryan Wahl also recently made the following trade(s):

• On Tuesday, March 18th, Bryan Wahl sold 3,341 shares of Tarsus Pharmaceuticals stock. The shares were sold at an average price of $46.29, for a total transaction of $154,654.89.

Tarsus Pharmaceuticals Trading Up 0.7 %

Shares of TARS opened at $49.91 on Friday. The company has a debt-to-equity ratio of 0.30, a quick ratio of 5.38 and a current ratio of 5.42. The firm has a market cap of $1.92 billion, a P/E ratio of -13.10 and a beta of 1.05. Tarsus Pharmaceuticals, Inc. has a fifty-two week low of $20.08 and a fifty-two week high of $57.28. The business has a 50-day moving average of $48.54 and a 200 day moving average of $45.06.

Tarsus Pharmaceuticals (NASDAQ:TARS) last released its earnings results on Tuesday, February 25th. The company reported ($0.60) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.68) by $0.08. Tarsus Pharmaceuticals had a negative return on equity of 55.86% and a negative net margin of 103.64%. The company had revenue of $66.41 million during the quarter, compared to the consensus estimate of $58.80 million. As a group, research analysts forecast that Tarsus Pharmaceuticals, Inc. will post -3.17 EPS for the current year.

Hedge Funds Weigh In On Tarsus Pharmaceuticals

Several hedge funds have recently made changes to their positions in TARS. Crowley Wealth Management Inc. bought a new position in shares of Tarsus Pharmaceuticals in the 4th quarter worth approximately $25,000. GF Fund Management CO. LTD. bought a new stake in Tarsus Pharmaceuticals during the fourth quarter worth about $44,000. R Squared Ltd purchased a new stake in Tarsus Pharmaceuticals in the fourth quarter worth about $53,000. FMR LLC lifted its holdings in shares of Tarsus Pharmaceuticals by 236.6% during the third quarter. FMR LLC now owns 5,032 shares of the company’s stock valued at $166,000 after purchasing an additional 3,537 shares during the last quarter. Finally, Quarry LP bought a new stake in shares of Tarsus Pharmaceuticals in the 4th quarter worth approximately $166,000. 90.01% of the stock is owned by hedge funds and other institutional investors.

Analysts Set New Price Targets

A number of equities analysts have commented on the company. Barclays reduced their price objective on Tarsus Pharmaceuticals from $62.00 to $60.00 and set an “overweight” rating on the stock in a research note on Wednesday, February 26th. Jefferies Financial Group boosted their target price on Tarsus Pharmaceuticals from $54.00 to $58.00 and gave the stock a “buy” rating in a research report on Thursday, March 6th. Oppenheimer lifted their target price on Tarsus Pharmaceuticals from $65.00 to $72.00 and gave the stock an “outperform” rating in a report on Wednesday, January 22nd. Guggenheim reaffirmed a “buy” rating and set a $78.00 price target (up previously from $75.00) on shares of Tarsus Pharmaceuticals in a research report on Monday, February 24th. Finally, HC Wainwright reissued a “buy” rating and set a $73.00 price objective on shares of Tarsus Pharmaceuticals in a research report on Wednesday, February 26th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, the stock has a consensus rating of “Buy” and a consensus price target of $63.67.

Tarsus Pharmaceuticals Company Profile

Tarsus Pharmaceuticals, Inc, a commercial stage biopharmaceutical company, focuses on the development and commercialization of novel therapeutic candidates for eye care in the United States. The company's lead product candidate is XDEMVY, a novel therapeutic for the treatment of blepharitis caused by the infestation of Demodex mites, as well as to treat meibomian gland disease.